Clinical Trials in Newark, New Jersey
6 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled531 locationsNCT06058377
Recruiting
Phase 2
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Non-Squamous Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI)42 enrolled34 locationsNCT05198830
Recruiting
Phase 2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled21 locationsNCT07102381
Recruiting
Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
NRG Oncology3,960 enrolled1209 locationsNCT05879926
Recruiting
Phase 3
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8+1 more
Alliance for Clinical Trials in Oncology1,295 enrolled829 locationsNCT05812807
Recruiting
Not Applicable
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Breast Cancer
Beth Israel Deaconess Medical Center402 enrolled11 locationsNCT06896474
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IVA Prostate Cancer AJCC v8
NRG Oncology1,209 enrolled383 locationsNCT05946213
Recruiting
Phase 2
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Hormone Receptor-Positive Breast Cancer
Rutgers, The State University of New Jersey40 enrolled7 locationsNCT06518837
Recruiting
Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Prostate Adenocarcinoma
NRG Oncology2,050 enrolled575 locationsNCT05050084
Recruiting
Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell Carcinoma+7 more
NRG Oncology269 enrolled242 locationsNCT06500455
Recruiting
Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8
NRG Oncology474 enrolled466 locationsNCT05624996
Recruiting
Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage I Prostate Cancer AJCC v8+2 more
NRG Oncology586 enrolled347 locationsNCT04134260
Recruiting
Phase 2Phase 3
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Previously Treated Non-Small Cell Lung Cancer
SWOG Cancer Research Network10,000 enrolled1201 locationsNCT03851445
Recruiting
Phase 2
Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted
Cardiac Toxicity
Rutgers, The State University of New Jersey60 enrolled10 locationsNCT05559164
Recruiting
Phase 4
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment
Breast NeoplasmsColorectal NeoplasmsHead and Neck Neoplasms+1 more
Rutgers, The State University of New Jersey100 enrolled12 locationsNCT07158164
Recruiting
Phase 2
ATATcH Alternating Treatment Plans for Advanced Cancer
Lung CancerHead and Neck Cancer
Rutgers, The State University of New Jersey150 enrolled11 locationsNCT05358548